Mangalam Organics: FY26 Turnaround Masks a Debt Trap
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
The world’s largest camphor maker just reported a 103% profit jump—but the narrative is split. Revenue grew 17.5%, reaching ₹623 Cr, and PAT vaulted from ₹12.5 Cr to ₹25.8 Cr on a one-time drop in raw material costs.
The catch: borrowings exploded 32% to ₹359 Cr. A July 2025 fire at the camphor plant—the company’s crown jewel—forced a ₹20 Cr inventory write-off and a ₹25 Cr fixed-asset loss, now in insurance limbo. The CRISIL rating sits on “Watch Developing” until the claim settles.
The retail segment (CamPure, Mangalam brands) is finally pulling weight—38% of revenue in FY26, doubling from 16% two years ago—but it still can’t offset the balance-sheet stretch.
Tension: Profitability gains meet rising leverage. Order books and new capacity have arrived, but working capital hasn’t turned. A ₹3,000 Cr net cash headline is absent.
2 — Introduction
Mangalam Organics trades in pine chemistry—a business that turns gum turpentine (the main input, 60–70% of COGS) into camphor, synthetic resins, and consumer home-care products.
Since 1981, the company has diversified from pure B2B (paint additives, fabric softeners, fragrance ingredients) into direct retail. In FY26, it crossed ₹30 Cr net profit for the first time since FY20, when it had logged ₹48 Cr. The journey between was jagged: FY23 saw a ₹27 Cr loss driven by raw material spikes and a fire-damaged balance sheet.
Management—led by founder heirs Kamal Kumar Dujodwala (Chairman, 42 years in chemicals) and Pannkaj Dujodwala (MD, 35 years in the business)—has signalled a pivot toward higher-margin intermediates (isobornyl acetate, terpineol, myrcene) to unlock value beyond commodity camphor. The pitch is execution, but the stage is set for Q1 of a multi-year recovery or a debt-spiral wake-up call.
Raw material prices spiked in late 2023–early 2024 (turpentine peaked at ~₹80/unit); they’ve since softened, gifting the company a ₹60+ Cr margin boost this year. The market isn’t pricing a commodity-price collapse, but it’s also watching how quickly that tailwind evaporates.
3 — Business Model: WTF Do They Even Do?
Four silos, one company.
B2B Terpenes (core, 62% of revenue). Camphor arrives in large drums and goes everywhere: temples (puja), pharma (balms), cosmetics (fragrances), paints (as a thinner), textiles (as a dye mordant). The company makes 10,000 MT/year of camphor now (expanded in 2022). Dipentene (orange-scent chemical), sodium acetate (dye fixer), isobornyl acetate (fragrance), and isoborneol (flavor) fill the rest. All are B2B industrial sales, priced on global turpentine spot and capacity utilization.
Synthetic Resins (12% of revenue). Terpene phenolic, alkyl phenolic, rosin esters—glue and paint additives made for Pidilite, Bostik, Henkel, adhesive houses. Low-margin commodity play, but sticky customer lock-in. Clients like rubber-tire makers (Goodyear, Bridgestone) and construction-adhesive OEMs keep reordering.
Retail/Direct-to-Consumer (26% of revenue, fastest-growing). Two brands, both on Amazon/Bigbasket. CamPure cones (car fresheners, wardrobe fresheners) and Mangalam camphor tablets (puja, premium Bhimseni camphor, gift boxes). Margins here are ~12%, vs. 5–7% on B2B. The segment logged ₹239 Cr revenue in FY26 and ₹12.2 Cr PAT—nearly half the company’s profit. It’s a low-capex, high-touch, DTC lever.
Raw Material Sourcing: Turpentine, the Elephant in the Room.
The company imports 60–70% of its gum turpentine from Indonesia, Brazil, Russia, Europe. Prices move on global supply shocks. In 2024, Indonesian and Russian supply tightened; in 2025, the market eased, and COGS fell ₹60 Cr YoY. The company has no hedging; it’s a price-taker.
The business is asset-lite if retail thrives; heavy-capex if B2B expansion chases every cycle.
Q4 (Mar 2026): Sales ₹153.62 Cr, PAT ₹5.98 Cr. Operating profit ₹46.65 Cr (+140% QoQ), but marred by a ₹19.8 Cr negative “Other Income” charge (reversal of fire-insurance accruals; see Section 6).
Concall Guidance (Feb 2026): Management expects retail to grow 25%+ in FY27 and maintain 11–12% EBITDA margins if raw-material prices stay in the ₹50–60/unit range. B2B capex for intermediate intermediates continues; Isoborneol Flakes capacity (Bhimseni) ramped to 2,500 MT/year in May 2025.
5 — Market Expectations & Historical Multiples
This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.
Metric
Current (Jun 2026, Price ₹527)
Historical Avg (3 Yr)
Peer Median
P/E
15.7
18.9
21.2
EV/EBITDA
8.68
12.5
10.2
ROE
9.31%
5.22%
11.4%
ROCE
10.46%
7.33%
12.0%
The market currently pays ₹527, implying a P/E of 15.7x on annualised FY26 EPS of ₹30.1 (full-year basis: ₹25.76 Cr PAT ÷ 0.856 Cr shares = ₹30.08).
This multiple sits below the peer median (21.2x) and below the company’s own 3-year average (18.9x). The gap suggests the market is pricing:
Raw-material volatility: Turpentine has oscillated ₹40–₹85/unit since 2022. If prices spike, B2B margins collapse.
Fire recovery uncertainty: Insurance claim size and timeline remain unresolved.
Leverage stress: Debt/equity is now 1.13x (up from 0.62x in Mar 2024). Interest coverage sits at 2.31x—tight.
